Steven Cohen Spring Works Therapeutics, Inc. Transaction History

Point72 Asset Management, L.P.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$36.5 - $52.5 $24.5 Million - $35.3 Million	-672,362 Reduced 31.1%	1,489,814 $73.3 Million
Q4 2023 Feb 14, 2024	BUY	$18.94 - $37.24 $31 Million - $60.9 Million	1,635,722 Added 310.71%	2,162,176 $78.9 Million
Q3 2023 Nov 14, 2023	BUY	$23.12 - $31.38 $1.44 Million - $1.96 Million	62,462 Added 13.46%	526,454 $12.2 Million
Q2 2023 Aug 14, 2023	BUY	$23.15 - $32.71 $10.7 Million - $15.2 Million	463,611 Added 121682.68%	463,992 $12.2 Million
Q1 2023 May 15, 2023	BUY	$24.97 - $34.05 $9,513 - $12,973	381 New	381 $9,000
Q4 2020 Feb 16, 2021	SELL	$48.36 - $77.92 $13.5 Million - $21.7 Million	-278,896 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$36.14 - $51.99 $629,450 - $905,509	17,417 Added 6.66%	278,896 $13.3 Million
Q2 2020 Aug 14, 2020	SELL	$22.98 - $48.57 $7.1 Million - $15 Million	-308,808 Reduced 54.15%	261,479 $11 Million
Q1 2020 May 15, 2020	BUY	$20.44 - $41.21 $11.7 Million - $23.5 Million	570,287 New	570,287 $15.4 Million

238

69.8M

144K

257K

Ticker SWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,401,100
Market Cap $2.43B
Description
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.